Email this article COMPARATIVE ANALYSIS OF THE EFFECT OF THE RADICAL TREATMENT OF DIFFUSE TOXIC GOITER ON THE INDICES OF THE HEALTH-RELATED QUALITY OF LIFE
- Authors: Nechaeva O.A.1,2, Dreval’ A.V.1,2, Mamedova T.R.1,2, Britvin T.A.1,2, Shestakova T.P.1,2, Komerdus I.V.1,2
-
Affiliations:
- Moscow Regional Research and Clinical Institute (MONIKI)
- 61/2 Shchepkina ul., Moscow, 129110, Russian Federation
- Issue: No 32 (2014)
- Pages: 24-30
- Section: ARTICLES
- URL: https://almclinmed.ru/jour/article/view/127
- DOI: https://doi.org/10.18786/2072-0505-2014-32-24-30
- ID: 127
Cite item
Full Text
Abstract
Background: Taking into account that many psychophysiological parameters directly depend on the severity and duration of pathological process and on the efficiency of treatment, investigations asessing remote results, health-related quality of life, and psychoemotional status of patients with a diffuse toxic goiter for a long time after radical treatment – are extremely urgent. Aim: To analyse the efficiency and safety of the radical methods of diffuse toxic goiter treatment, to compare the indices of the health-related quality of life, anxiety and depression levels depending on the kind of chosen methods of radical treatment. Materials and methods: A total of 71 patients with a diffuse toxic goiter were recruited into the study (37 patients who agreed radioiodine therapy, and 34 patients who underwent subtotal resection of the thyroid gland). Clinical examination, laboratory and instrumental analyses were carried out prior to and in 12 months after treatment. The questionnaire MOS SF-36 was used to estimate the health-related quality of life, Spillberg’s Anxiety Scale – to assess the levels of enxiety, and Beck Depression Inventory – to assess the level of depression. Results: In the group of radioiodine therapy, the median of therapeutic activity was 12.7 [8.5; 15.2] mKi. After radioiodine therapy, the aim of treatment (hypothyroidism) was achieved in 95% of cases, and in 100% of cases – after subtotal thyroid resection. The MOS SF-36 questionnaire showed that the indices of the health-related quality of life in patients became significantly higher, and the anxiety level in 12 months after treatment – significantly lower than those before treatment (р<0.05). Conclusion: The obtained results demonstrated the effectiveness of both methods used for treatment of Grave’s disease. The type of radical treatment made no difference. Compared with the initial thyrotoxicosis, compensated hypothyroidism in both cases was followed by a significantly higher quality of life and lower levels of anxiety and depression. It was also shown that people who received radical treatment, despite compensated hypothyroidism, overall, had lower quality of life, than those who did not have thyroid disease.
About the authors
O. A. Nechaeva
Moscow Regional Research and Clinical Institute (MONIKI); 61/2 Shchepkina ul., Moscow, 129110, Russian Federation
Author for correspondence.
Email: olga1185@yandex.ru
MD, PhD, senior researcher, Department of Therapeutic Endocrinology, MONIKI Russian Federation
A. V. Dreval’
Moscow Regional Research and Clinical Institute (MONIKI); 61/2 Shchepkina ul., Moscow, 129110, Russian Federation
Email: fake@neicon.ru
MD, PhD, Professor, Head of the Department of Therapeutic Endocrinology, MONIKI; Chief Endocrinologist of the Moscow Region Russian Federation
T. R. Mamedova
Moscow Regional Research and Clinical Institute (MONIKI); 61/2 Shchepkina ul., Moscow, 129110, Russian Federation
Email: fake@neicon.ru
MD, PhD, researcher of the Department of Therapeutic Endocrinology, MONIKI Russian Federation
T. A. Britvin
Moscow Regional Research and Clinical Institute (MONIKI); 61/2 Shchepkina ul., Moscow, 129110, Russian Federation
Email: fake@neicon.ru
MD, PhD, Head of the Department of Surgical Endocrinology, MONIKI.
Russian FederationT. P. Shestakova
Moscow Regional Research and Clinical Institute (MONIKI); 61/2 Shchepkina ul., Moscow, 129110, Russian Federation
Email: fake@neicon.ru
MD, PhD, Assistant Professor of the Chair of Endocrinology, the Faculty of Postgraduate Medical Education, MONIKI.
Russian FederationI. V. Komerdus
Moscow Regional Research and Clinical Institute (MONIKI); 61/2 Shchepkina ul., Moscow, 129110, Russian Federation
Email: fake@neicon.ru
MD, PhD, Assistant of the Chair of Endocrinology, the Faculty of Postgraduate Medical Education, MONIKI
Russian FederationReferences
- Benker G, Reinwein D, Kahaly G, Tegler L, Alexander WD, Fassbinder J, Hirche H. Is there a methimazole dose effect on remission rate in Graves’ disease? Results from a long-term prospective study. The European Multicentre Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs. Clin Endocrinol (Oxf). 1998;49(4):451-7.
- Балаболкин МИ, Клебанова ЕМ, Креминская ВМ. Дифференциальная диагностика и лечение эндокринных заболеваний (руководство). М.: Медицина; 2002. (Balabolkin MI, Klebanova EM, Kreminskaya VM. [Differencial diagnosis and treatment of endocrine diseases (manual)]. Moscow: Meditsina; 2002. Russian).
- Дедов ИИ, Мельниченко ГА, Фадеев ВВ. Эндокринология: учебник. М.: Медицина; 2000. (Dedov II, Mel’nichenko GA, Fadeev VV. [Endocrinology: textbook]. Moscow: Meditsina; 2000. Russian).
- Ruchała M, Sowiński J, Dolata M, Junik R, Gembicki M, Skiba A. Radioiodine treatment of hyperthyroidism in patients with low thyroid uptake. Nucl Med Rev Cent East Eur. 2005;8(1):28-32.
- Фадеев ВВ, Дроздовский БЯ, Гусева ТН, Мельниченко ГА, Бузиашвили ИИ, Гарбузов ПИ. Отдаленные результаты лечения токсического зоба радиоактивным 131I. Проблемы эндокринологии. 2005;51(1):3-10. (Fadeev VV, Drozdovskiy BYa, Guseva TN, Mel’nichenko GA, Buziashvili II, Garbuzov PI. [Remote results of the toxic goiter treatment with 131I]. Problemy endokrinologii. 2005;51(1):3-10. Russian).
- Pineda P, Michelsen H, Rivera M, Lillo R, Massardo T, Araya V, Sierralta P, Oviedo S, Liberman C. Treatment of hyperthyroidism with radioiodine: effects of administered dose on complications and thyroid function. Rev Med Chil. 2000;128(5):499-507.
- Фадеев ВВ, Петрова НД. Из истории лечения тиреотоксикоза радиоактивным йодом в России. Проблемы эндокринологии. 1988;44(2):54. (Fadeev VV, Petrova ND. [From the history of thyreotoxicosis treatment with radioactive iodine in Russia]. Problemy endokrinologii. 1988;44(2):54. Russian).
- Parle JV, Franklyn JA, Cross KW, Jones SC, Sheppard MC. Prevalence and follow-up of abnormal thyrotrophin (TSH) concentrations in the elderly in the United Kingdom. Clin Endocrinol (Oxf). 1991;34(1):77-83.
- Reinwein D, Benker G, Lazarus JH, Alexander WD. A prospective randomized trial of antithyroid drug dose in Graves’ disease therapy. European Multicenter Study Group on Antithyroid Drug Treatment. J Clin Endocrinol Metab. 1993;76(6):1516-21.
- Surks MI, Schadlow AR, Stock JM, Oppenheimer JH. Determination of iodothyronine absorption and conversion of L-thyroxine (T 4) to L-triiodothyronine (T 3) using turnover rate techniques. J Clin Invest. 1973;52(4):805-11.
- Huysmans DA, Corstens FH, Kloppenborg PW. Long-term follow-up in toxic solitary autonomous thyroid nodules treated with radioactive iodine. J Nucl Med. 1991;32(1):27-30.
- Pauwels EK, Smit JW, Slats A, Bourguignon M, Overbeek F. Health effects of therapeutic use of 131I in hyperthyroidism. Q J Nucl Med. 2000;44(4):333-9.
- Angusti T, Codegone A, Pellerito R, Favero A. Thyroid cancer prevalence after radioiodine treatment of hyperthyroidism. J Nucl Med. 2000;41(6):1006-9.
- Ванушко ВЭ, Федак ИР. Гипотиреоз как исход хирургического лечения диффузного токсического зоба. Лечащий врач. 2005;(8):38-41. (Vanushko VE, Fedak IR. [Hypothyroidism as an outcome of surgical treatment of the diffuse toxic goiter]. Lechashchiy vrach. 2005;(8):38-41. Russian).
- Berchtold R, Studer H, Teuscher J. Operative strategy in thyroid autonomy and Basedow hyperthyroidism. Langenbecks Arch Chir. 1985;366:51-4.
- Miccoli P, Vitti P, Rago T, Iacconi P, Bartalena L, Bogazzi F, Fiore E, Valeriano R, Chiovato L, Rocchi R, Pinchera A. Surgical treatment of Graves’ disease: subtotal or total thyroidectomy? Surgery. 1996;120(6):1020-4.
- Palit TK, Miller CC 3rd, Miltenburg DM. The efficacy of thyroidectomy for Graves’ disease: A meta-analysis. J Surg Res. 2000;90(2):161-5.
- Farkas EA, King TA, Bolton JS, Fuhrman GM. A comparison of total thyroidectomy and lobectomy in the treatment of dominant thyroid nodules. Am Surg. 2002;68(8):678-82.
- Forde I, Corgie D, Trainer PJ. Outcome at two years of fixed dose radioiodine treatment for thyrotoxicosis. Endocrine Abstracts. Proceedings of the 21st Joint Meeting of the British Endocrine Societies; 2002 April 8-11; Harrogate, UK. Poster 285.
- Werga-Kjellman P, Zedenius J, Tallstedt L, Träisk F, Lundell G, Wallin G. Surgical treatment of hyperthyroidism: a ten-year experience. Thyroid. 2001;11(2):187-92.
- Крылов ВВ, Гарбузов ПИ, Дроздовский БЯ, Олейник НА, Романко СИ, Гордеева МС, Власова ОП, Доля ОП, Матусевич ЕС, Клепов АН. Социально-психологические аспекты радионуклидной терапии и качество жизни больных тиреотоксикозом при лечении радиоактивным йодом. Фундаментальные исследования. 2007(12 Часть 2):289-90. (Krylov VV, Garbuzov PI, Drozdovskiy BYa, Oleynik NA, Romanko SI, Gordeeva MS, Vlasova OP, Dolya OP, Matusevich ES, Klepov AN. [Social-and-psychologic aspects of radionuclide therapy and the quality of life in patients with thyreotoxicosis treated with radioactive iodine]. Fundamental’nye issledovaniya. 2007(12 Pt 2):289-90. Russian).
- Новик АА, Ионова ТИ. Руководство по исследованию качества жизни в медицине. М.: Олма Медиа Групп; 2007. (Novik AA, Ionova TI. Manual on studying the quality of life in medicine. Moscow: Olma Media Grupp; 2007. Russian).
- Bullinger M, Alonso J, Apolone G, Leplège A, Sullivan M, Wood-Dauphinee S, Gandek B, Wagner A, Aaronson N, Bech P, Fukuhara S, Kaasa S, Ware JE Jr. Translating health status questionnaires and evaluating their quality: the IQOLA Project approach. International Quality of Life Assessment. J Clin Epidemiol. 1998;51(11):913-23.
- Fairclough D. Method of analysis for longitudinal studies of health-related quality of life. In: Quality of Life Assessment in Clinical Trials. Oxford – N.Y. – Tokyo: Oxford University Press; 1998. p. 227-47.
Supplementary files
